The advancement of cancer chemoprevention by revision of clinical trial strategies

Panminerva Medica

Volumn 44, Issue 1, 2002, Pages 41-45

  Sharma, R A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Anticarcinogenic agents; Chemotherapy, adjuvant; Cyclooxygenase inhibitors; Neoplasms, prevention and control

Indexed keywords

CHEMOPROPHYLAXIS; CLINICAL TRIAL; HUMAN; METHODOLOGY; NEOPLASM; REVIEW;

CHEMOPREVENTION; CLINICAL TRIALS; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 0036514739     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Tattersall MHN, Thomas H. Recent advances: oncology. Br Med J 1999;318:445-8.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Gelman KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999;91:1281-7.
4. Perera FP. Molecular epidemiology: on the path to prevention? J Natl Cancer Inst 2000;8:602-12.
5. Wattenberg LW. Chemoprophylaxis of carcinogenesis: a review. Cancer Res 1966;26:1520-6.
6. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 1998;90:1514-28.
7. Sharma RA, Gescher A, O'Byrne KJ, Steward WP. Familiar drugs may prevent cancer. Postgrad Med J 2001;77:492-7.
8. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525-30.
9. Chemoprevention Working Group. Prevention of cancer in the next millenium: report of the chemoprevention working group to the American Association for Cancer Research. Cancer Res 1999;59:4743-58.
10. Kelloff GJ, Crowell JA, Hawk ET, Steel VE, Lubet RA, Boone CW et al. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem 1996;26S:54-71.
11. Sharma RA, Manson MM, Gescher A, Steward WP. Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents. Eur J Cancer 2001;37:12-22.
12. De Flora S, Balansky R, Scatolini L, Di Marco C, Gasparini L, Orlando M et al. Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention. In: Stewart BW, McGregor D, Kleihues P, editors. Principles of chemoprevention. IARC Scientific Publications No.139: Lyon, 1986:291-301.
13. The α-Tocopherol, β-carotene Cancer Prevention Study Group. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
14. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A. Risk factors for lung cancer and for intervention effects in CARET, the β-carotene and retinol efficacy trial. J Natl Cancer Inst 1996;88:1550-9.
15. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JN, Marshall JR, van Leeuwen B et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 2000;342:1156-62.
16. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. N Engl J Med 2000;342:1149-55.
17. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
18. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000;18:1967-79.
19. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328(18):1313-6.
20. Collet J-P, Sharpe C, Belzile E, Boivin J-F, Hanley J, Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62-8.
21. Are rofecoxib and celecoxib safer NSAIDs? Drug Ther Bull 2000;38:81-6.
22. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M68-M78.
23. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342(26):1946-52.
24. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M et al. Combined interferon-α, 13-cis-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001;19:3010-7.
25. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
26. Huang ME, Ye YC, Chen SR, Chai SR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 1988;72:567-72.
27. Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q et al. Effect of retinol in preventing squamous cell skin cancer in moderaterisk subjects: a randomised double-blind controlled trial. Cancer Epidemiol Biomarkers Prev 1997;6:949-56.
28. Vigushin DM, Poon GK, Boddy A, Jarman M, Coombes RC. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Chemother Pharmacol 1998;42:111-7.
29. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 2000;6:390-6.
30. Pisters KMW, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001;19:1830-8.
31. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894-900.
32. Gescher AJ, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a salutary tale of failure and promise. Lancet Oncol 2001;2:371-9.
33. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA et al. Multivitamin use, folate and colon cancer in women in the Nurses' Helath Study. Ann Intern Med 1998;129:517-24.
34. Clapper ML, Szarka CE. Glutathione S-transferases - biomarkers of cancer risk and chemopreventive response. Chem-Biol Interact 1998;111-112:377-88.
35. Szarka CE, Pfeiffer GR, Hum ST, Everley LC, Balshem AM, Moore DF. Glutathione S-transferase activity and glutathione S-transferase expression in subjects with risk for colorectal cancer. Cancer Res 1995;55:2789-93.
36. O'Dwyer PJ, Szarka CE, Yao K-S. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 1996;98:1210-7.
37. Einspahr JG, Alberts DA, Gapstur SM, Bostick RM, Emerson SS, Gerner EW. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epid Biomarkers Prev 1997;6:37-48.
38. Alberts DS. Advanced clinical trial design: the use of surrogate end point biomarkers in cancer chemoprevention trials. In: Perry MC, editor. American Society of Clinical Oncology Educational Book. Baltimore (USA): Lippincott, 1999:76-80.